Affiliated with Université Laval & CERVO Research Centre

Chloride extrusion enhancers as novel therapeutics for neurological diseases.

TitleChloride extrusion enhancers as novel therapeutics for neurological diseases.
Publication TypeJournal Article
Year of Publication2013
AuthorsGagnon M, Bergeron MJ, Lavertu G, Castonguay A, Tripathy S, Bonin RP, Perez-Sanchez J, Boudreau D, Wang B, Dumas L, Valade I, Bachand K, Jacob-Wagner M, Tardif C, Kianicka I, Isenring P, Attardo G, Coull JAM, De Koninck Y
JournalNat Med
Volume19
Issue11
Pagination1524-8
Date Published2013 Nov
ISSN1546-170X
KeywordsAnalgesics, Animals, Chlorides, CHO Cells, Cricetinae, Cricetulus, Disease Models, Animal, HEK293 Cells, High-Throughput Screening Assays, Humans, Intracellular Fluid, Ion Transport, Male, Nervous System Diseases, Neuralgia, Rats, Rats, Sprague-Dawley, Symporters, Thiazolidines
Abstract

The K(+)-Cl(-) cotransporter KCC2 is responsible for maintaining low Cl(-) concentration in neurons of the central nervous system (CNS), which is essential for postsynaptic inhibition through GABA(A) and glycine receptors. Although no CNS disorders have been associated with KCC2 mutations, loss of activity of this transporter has emerged as a key mechanism underlying several neurological and psychiatric disorders, including epilepsy, motor spasticity, stress, anxiety, schizophrenia, morphine-induced hyperalgesia and chronic pain. Recent reports indicate that enhancing KCC2 activity may be the favored therapeutic strategy to restore inhibition and normal function in pathological conditions involving impaired Cl(-) transport. We designed an assay for high-throughput screening that led to the identification of KCC2 activators that reduce intracellular chloride concentration ([Cl(-)]i). Optimization of a first-in-class arylmethylidine family of compounds resulted in a KCC2-selective analog (CLP257) that lowers [Cl(-)]i. CLP257 restored impaired Cl(-) transport in neurons with diminished KCC2 activity. The compound rescued KCC2 plasma membrane expression, renormalized stimulus-evoked responses in spinal nociceptive pathways sensitized after nerve injury and alleviated hypersensitivity in a rat model of neuropathic pain. Oral efficacy for analgesia equivalent to that of pregabalin but without motor impairment was achievable with a CLP257 prodrug. These results validate KCC2 as a druggable target for CNS diseases.

DOI10.1038/nm.3356
Alternate JournalNat. Med.
Full Text
PubMed ID24097188
PubMed Central IDPMC4005788
Grant List12942-2 / / Canadian Institutes of Health Research / Canada
/ / Canadian Institutes of Health Research / Canada